Femasys Inc. has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its FemVue Controlled device, a next-generation diagnostic solution designed for controlled contrast delivery to evaluate fallopian tube status. The FemVue Controlled device integrates features from the company's original FemVue and FemChec technologies into a single FDA-cleared product, supporting multiple clinical uses and improving workflow efficiency for clinicians.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604194-en) on December 18, 2025, and is solely responsible for the information contained therein.